Maybe if BB's stick around our stelar record of no serious side effects will no longer hold.
From what I've heard I don't think that will happen because cells that express PS don't need to survive and they're the only kinds of cells that are targeted. But you're right, that's why they do clinical trials.
It has been known for some time that ß2-glycoprotein I plays a role in Anti-Phospholipid Syndrome (APS). However, APS antibodies recognize domain I of ß2GPI. The bavi betabodies constructs use ß2GPI polypeptides that comprise binding regions from domain V and lack domain I of ß2GPI. So the introduction of such betabodies should not present any safety concern from this standpoint as the domain V only binds phosphatidylserine, which is not expressed on normal cell surfaces.
News 
Market Data 
Discover 
AI
